Bausch Health Companies Inc. (NYSE:BHC) Receives $7.75 Average Price Target from Analysts

Shares of Bausch Health Companies Inc. (NYSE:BHC) have earned an average rating of “Hold” from the seven research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $7.75.

A number of research analysts recently issued reports on BHC shares. Royal Bank of Canada lifted their target price on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Friday, November 1st. Jefferies Financial Group lowered their price objective on shares of Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, August 7th. Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Finally, StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th.

Bausch Health Companies Price Performance

Bausch Health Companies stock opened at $8.37 on Wednesday. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46. The stock has a market capitalization of $3.01 billion, a PE ratio of -17.44 and a beta of 0.74. The firm has a 50 day simple moving average of $8.41 and a 200-day simple moving average of $7.14.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The firm had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same period last year, the company posted $1.03 EPS. The firm’s quarterly revenue was up 12.2% on a year-over-year basis. On average, analysts forecast that Bausch Health Companies will post 3.74 earnings per share for the current fiscal year.

Insider Transactions at Bausch Health Companies

In related news, EVP Seana Carson sold 13,370 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $6.21, for a total transaction of $83,027.70. Following the completion of the sale, the executive vice president now directly owns 435,198 shares of the company’s stock, valued at approximately $2,702,579.58. This represents a 2.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.12% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bausch Health Companies

A number of hedge funds have recently bought and sold shares of BHC. Headlands Technologies LLC bought a new position in shares of Bausch Health Companies in the second quarter worth about $35,000. MQS Management LLC acquired a new position in shares of Bausch Health Companies during the second quarter worth approximately $71,000. Certuity LLC bought a new stake in shares of Bausch Health Companies in the second quarter valued at approximately $75,000. Bfsg LLC grew its stake in shares of Bausch Health Companies by 46.7% in the second quarter. Bfsg LLC now owns 11,450 shares of the company’s stock worth $80,000 after acquiring an additional 3,643 shares during the last quarter. Finally, Kendall Capital Management bought a new position in Bausch Health Companies during the second quarter worth $87,000. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.